Market Overview:
The global anti-FGF1 antibody market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising investments by key players in R&D for novel therapies, and growing demand for monoclonal antibodies. Based on type, the global anti-FGF1 antibody market is segmented into 30 microgram, 40 microgram, 50 microgram, 100 microgram and other segments. The 100 microgram segment is expected to account for the largest share of the global anti-FGF1 antibody market in 2018. This large share can be attributed to factors such as rising demand for targeted therapies and increasing incidence of cancer. Based on application, the global anti-FGF1 antibody market is segmented into experimental study and other segments.
Product Definition:
An antibody that binds to and neutralizes FGF1, a growth factor involved in cell proliferation and differentiation. Anti-FGF1 antibodies may be useful for the treatment of cancer or other diseases mediated by FGF1 activity.
30 Microgram:
30 microgram is a unit used for measuring the amount of protein. It's also known as ug and represented by the symbol "ug". One ug (microgram) of FGF1 protein contains 30 x 1023 molecules, which is equal to 300 million molecules or 3 billionths of a gram. The International Union for Conservation of Nature has declared that no more than 20% (%)of feline genetic material can be used in breeding programs.
40 Microgram:
40 microgram is used for the production of monoclonal antibodies. It is also used in the diagnosis and treatment of cancer, multiple sclerosis, rheumatoid arthritis and other autoimmune diseases.
Application Insights:
The experimental study segment dominated the global market in terms of revenue share in 2017. The high penetration of this application is primarily attributed to the extensive R&D activities undertaken by various institutions and biopharmaceutical companies for the development of novel anti-FGF1 antibodies for cancer treatment, wound healing, and other diseases.
A number of research studies have indicated that FGF signaling pathway plays a significant role in tumorigenesis, angiogenesis, metastasis formation as well as during chronic inflammatory conditions such as arthritis and periodontitis. This has resulted in an increased focus on targeting FGFs with antibodies for therapeutic purposes across several preclinical models. However, a large number of clinical trials are required to validate these promising results before they can be applied therapeutically.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing R&D, presence of key manufacturers and a large number of clinical trials being conducted for the development of novel therapeutics targeting fibroblast growth factor 1 (FGF1). Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income, expanding healthcare infrastructure and growing awareness pertaining to advanced therapies for cancer treatment.
Key players operating in this space include Santa Cruz Biotechnology; CELGENE CORP.; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the key growth drivers for the anti-FGF1 antibody market. FGF1 is overexpressed in various types of cancers, including breast, ovarian, and pancreatic cancers. This has led to the development of several anti-FGF1 antibodies for the treatment of these cancers.
- Growing demand for targeted therapies: The growing demand for targeted therapies is another key growth driver for the anti-FGF1 antibody market. FGF1 has been shown to play a role in tumorigenesis and progression, making it an attractive target for therapeutic intervention. This has led to the development of several novel anti-FGF1 antibodies that specifically target this protein molecule.
- Rising incidence rates of cancer: The rising incidence rates of cancer are also driving growth in the anti-FGF1 antibody market as more patients are seeking treatment options that can help them overcome their disease condition.. Additionally, increasing awareness about available treatments is also contributing to market growth..
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-FGF1 Antibody Market Research Report
By Type
30 Microgram, 40 Microgram, 50 Microgram, 100 Microgram, Other
By Application
Experimental Study, Other
By Companies
LifeSpan BioSciences, Thermofisher Scientific, Santa Cruz Biotechnology, Merck KGaA, Abcam, Novus Biologicals, GeneTex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Anti-FGF1 Antibody Market Report Segments:
The global Anti-FGF1 Antibody market is segmented on the basis of:
Types
30 Microgram, 40 Microgram, 50 Microgram, 100 Microgram, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Experimental Study, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- LifeSpan BioSciences
- Thermofisher Scientific
- Santa Cruz Biotechnology
- Merck KGaA
- Abcam
- Novus Biologicals
- GeneTex
Highlights of The Anti-FGF1 Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 30 Microgram
- 40 Microgram
- 50 Microgram
- 100 Microgram
- Other
- By Application:
- Experimental Study
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-FGF1 Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-FGF1 antibody is a type of antibody that targets the FGF1 protein. This protein is involved in many cellular processes, including growth and development. Anti-FGF1 antibodies can block the actions of this protein, which may lead to improvements in various medical conditions associated with FGF1 activity.
Some of the key players operating in the anti-fgf1 antibody market are LifeSpan BioSciences, Thermofisher Scientific, Santa Cruz Biotechnology, Merck KGaA, Abcam, Novus Biologicals, GeneTex.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-FGF1 Antibody Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-FGF1 Antibody Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-FGF1 Antibody Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-FGF1 Antibody Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-FGF1 Antibody Market Size & Forecast, 2020-2028
4.5.1 Anti-FGF1 Antibody Market Size and Y-o-Y Growth
4.5.2 Anti-FGF1 Antibody Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 30 Microgram
5.2.2 40 Microgram
5.2.3 50 Microgram
5.2.4 100 Microgram
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Experimental Study
6.2.2 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-FGF1 Antibody Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-FGF1 Antibody Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 30 Microgram
9.6.2 40 Microgram
9.6.3 50 Microgram
9.6.4 100 Microgram
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Experimental Study
9.10.2 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 30 Microgram
10.6.2 40 Microgram
10.6.3 50 Microgram
10.6.4 100 Microgram
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Experimental Study
10.10.2 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 30 Microgram
11.6.2 40 Microgram
11.6.3 50 Microgram
11.6.4 100 Microgram
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Experimental Study
11.10.2 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 30 Microgram
12.6.2 40 Microgram
12.6.3 50 Microgram
12.6.4 100 Microgram
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Experimental Study
12.10.2 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 30 Microgram
13.6.2 40 Microgram
13.6.3 50 Microgram
13.6.4 100 Microgram
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Experimental Study
13.10.2 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-FGF1 Antibody Market: Competitive Dashboard
14.2 Global Anti-FGF1 Antibody Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 LifeSpan BioSciences
14.3.2 Thermofisher Scientific
14.3.3 Santa Cruz Biotechnology
14.3.4 Merck KGaA
14.3.5 Abcam
14.3.6 Novus Biologicals
14.3.7 GeneTex
